Clinical Trials Logo

Prostatic Diseases clinical trials

View clinical trials related to Prostatic Diseases.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06190899 Recruiting - Prostate Cancer Clinical Trials

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Start date: January 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combination with darolutamide in subjects with mCRPC.

NCT ID: NCT05902637 Recruiting - Prostate Cancer Clinical Trials

The Efficacy Of Mapping For Cognitive Prostate Biopsy

MAPROSTATE
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Today, many centers still perform Magnetic Resonance Imaging (MRI) cognitive prostate biopsy. The efficacy of detecting clinically significant prostate cancer, which is thought to be due to the experience of the urologist who performed the sampling and the difference in experience of the radiologists who performed the Multiparametric Prostate Magnetic Resonance (MPMR) evaluation, has been reported between 25% and 34% in the literature. In order to eliminate this reporting and sampling difference, The goal of this interventional study is to compare the effectiveness of Multiparametric Prostate Magnetic Resonance (MPMR) Imaging routinely taken before biopsy with a single-center randomized and prospective study and prostate biopsies to be performed by the same urologist with the mapping technique created by a single genitourinary radiologist working in our center with standard cognitive prostate biopsy and to contribute to the literature Type of study: Clinical trial participant population: Male patients with elevated serum Prostate Specific Antigen (PSA) or indicated prostate biopsy by Magnetic Resonance Imaging (MRI) imaging and underwent Multiparametric Prostate Magnetic Resonance (MPMR) before the procedure Participants will undergo transrectal prostate biopsy with or without mapping, Researches will compare to see if the cancer detection rates differ

NCT ID: NCT05413850 Recruiting - Prostate Cancer Clinical Trials

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Start date: July 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

NCT ID: NCT04656678 Recruiting - Prostate Cancer Clinical Trials

Focal US-guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Intermediate Risk Prostate Cancer

Start date: November 25, 2020
Phase: N/A
Study type: Interventional

The purpose of this research study is to determine the safety and feasibility of using the UroNav software and DynaCAD software for planning and treating prostate cancer as an add on to the already approved workflow of using ultrasound only during the cryoablation of the prostate. The software application may aid doctors in locating a prior biopsy proven cancer location from the UroNav biopsy that patients previously had and then use that information to guide the treatment.

NCT ID: NCT04599218 Recruiting - Prostate Cancer Clinical Trials

MR/TRUS Fusion Guided Prostate Biopsy - An Improved Way to Detect and Quantify Prostate Cancer

Start date: August 21, 2020
Phase: N/A
Study type: Interventional

This research study is designed to determine if targeted Magnetic Resonance Imaging (MRI) Ultrasound (US) fusion biopsy is better than the standard of care ultrasound guided biopsy alone in diagnosing subjects with clinically significant prostate cancer with MRI visible lesions. This study will consist of comparing the standard of care (ultrasound guided prostate biopsy) with the protocol biopsy which consists of an ultrasound guided prostate biopsy and a MRI/US fusion tracked prostate biopsy.

NCT ID: NCT04462926 Recruiting - Prostate Cancer Clinical Trials

Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed

PSMA-PROSTAPET
Start date: September 20, 2020
Phase: N/A
Study type: Interventional

This is a diagnostic accuracy prospective, single-centre, open-label, single group assignment interventional study. Its aim is to evaluate the diagnostic accuracy of [68Ga]Ga-PSMA-11 PET/CT in detection of primary tumour and extra prostatic disease (lymph node, soft tissues spread or bone metastases) in men newly diagnosed with Prostate Cancer at Intermediate and High Risk, according to 2019 Prostate Cancer EAU Guidelines Risk Group Stratification (see Study Population paragraph). The investigators are interested in the possible future role of [68Ga]Ga-labelled PSMA PET/CT as integration to conventional imaging mpMRI (with or without CT of the lower abdomen and Bone scan) in the detection of primary tumor and extra-prostatic disease (lymph node and soft tissues spread or bone metastases).

NCT ID: NCT04288427 Recruiting - Clinical trials for Benign Prostatic Hyperplasia

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy

Start date: September 25, 2020
Phase: N/A
Study type: Interventional

The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified prior to offering this treatment and they can be offered alternative treatment strategies in its place. The aim is to see if noninvasive techniques such as MRI can detect inflammation of the prostate to assist with early detection of those who will and who will not respond to Finasteride.

NCT ID: NCT04026763 Recruiting - Prostate Disease Clinical Trials

MR/TRUS Fusion Guided Prostate Biopsy

Start date: May 11, 2018
Phase: N/A
Study type: Interventional

This study will determine if targeted (Magnetic Resonance (MR) / Ultrasound (US) fusion biopsy) plus conventional biopsy is superior to conventional biopsy alone in diagnosing subjects with prostate cancer.

NCT ID: NCT03711643 Recruiting - Prostatic Diseases Clinical Trials

Hypnosis Mask: a New Approach to Management of Pain in Medical Imaging

HYPNOTIC
Start date: May 7, 2019
Phase: N/A
Study type: Interventional

The prostatic biopsies echo-guided are a painful and stressful. The purpose is to test a new medical device created recently, " Hypnos-Pro ", wich uses connected technologies. This connected device is a mask with diodes coupled with an audio headset and a touch pad. This connected mask is an another option to induce an hypnotic state for our patients. the objective is to value hypnotic mask effectiveness, to reduce the level pain and anxiety for the patients who benefit a prostatic biopsies echo-guided with local anesthesia.